MicroActive Resveratrol (Polygonum cuspidatum)

MicroActive Resveratrol is a sustained-release form of trans-resveratrol extracted from Polygonum cuspidatum, standardized to over 73.8% trans-resveratrol content. It activates the longevity-associated sirtuin SIRT1 and inhibits NF-κB signaling, positioning it as a potent antioxidant and anti-inflammatory compound.

Origin & History

MicroActive Resveratrol is a branded, sustained-release formulation of resveratrol derived from the roots of Polygonum cuspidatum (Japanese knotweed), a plant native to East Asia. It is extracted via reflux with 95% ethanol, followed by acid hydrolysis, liquid-liquid extraction, and purification, yielding >73.8% purity resveratrol.

Historical & Cultural Context

Polygonum cuspidatum is a well-known traditional Chinese medicine, historically used as a source of resveratrol. Specific traditional indications and duration of use are not detailed in the available research.

Health Benefits

• No clinical evidence available - search results contain no human trials on MicroActive Resveratrol
• Traditional use documented - P. cuspidatum is used in traditional Chinese medicine as a resveratrol source
• High purity extract - standardized to >73.8% trans-resveratrol content
• Contains multiple bioactives - includes trans-resveratrol, polydatin, and emodin compounds
• Sustained-release formulation - branded ingredient designed for extended release (no clinical data on release profile)

How It Works

Trans-resveratrol activates SIRT1 (sirtuin-1), a NAD+-dependent deacetylase that regulates gene expression linked to cellular longevity, mitochondrial biogenesis, and inflammation. It also inhibits NF-κB transcription factor activity, reducing downstream production of pro-inflammatory cytokines such as TNF-α and IL-6. Additionally, trans-resveratrol scavenges reactive oxygen species (ROS) directly and upregulates endogenous antioxidant enzymes including superoxide dismutase (SOD) and catalase.

Scientific Research

No human clinical trials, RCTs, or meta-analyses were found in the search results for MicroActive Resveratrol or resveratrol from P. cuspidatum. No PubMed PMIDs are available as no clinical studies were identified.

Clinical Summary

No published human clinical trials have been conducted specifically on the MicroActive Resveratrol branded form to date, making direct evidence-based claims premature. General resveratrol research includes small randomized controlled trials — typically 20 to 60 participants — examining metabolic, cardiovascular, and cognitive outcomes, often using doses between 150 mg and 1000 mg daily with mixed results. The MicroActive delivery technology is designed to improve the notoriously poor bioavailability of standard resveratrol (oral bioavailability under 1%), theoretically improving plasma concentration, but this has not been validated in large-scale trials. Until brand-specific clinical data are published, efficacy conclusions should be drawn cautiously from general resveratrol literature.

Nutritional Profile

MicroActive Resveratrol is a sustained-release, microencapsulated extract derived from Polygonum cuspidatum (Japanese knotweed) root. It is not a macronutrient source and provides negligible calories, protein, fat, carbohydrates, or fiber at typical supplement doses (100–500 mg/day). **Primary bioactive compounds:** • **trans-Resveratrol (3,5,4'-trihydroxystilbene):** Standardized to >73.8% by weight; this is the principal active polyphenolic stilbene. A 250 mg dose delivers approximately 185 mg trans-resveratrol. • **Polydatin (resveratrol-3-O-β-glucoside):** Present as a naturally co-occurring glycosylated form of resveratrol, typically 5–15% of total extract; acts as a prodrug converting to free resveratrol in vivo. • **Emodin (1,3,8-trihydroxy-6-methylanthraquinone):** A minor anthraquinone constituent naturally present in P. cuspidatum, generally <2–5% of extract; possesses independent bioactivity but is not the target compound. **Micronutrients:** Trace amounts of minerals inherent to the plant matrix (negligible at supplement doses). No significant vitamin content. **Bioavailability notes:** Unformulated trans-resveratrol has notoriously poor oral bioavailability (~1–5% as free resveratrol) due to rapid Phase II conjugation (sulfation and glucuronidation) in the intestinal epithelium and liver. The MicroActive sustained-release matrix uses a proprietary microencapsulation technology (typically involving starch or lipid carriers) designed to provide gradual release over approximately 12 hours, which may improve the area-under-the-curve (AUC) for plasma resveratrol compared to immediate-release forms. Manufacturer-sponsored pharmacokinetic data suggest 2× greater bioavailability and more consistent plasma levels versus standard resveratrol, though independent peer-reviewed human PK validation is limited. Primary circulating metabolites include resveratrol-3-O-sulfate and resveratrol-3-O-glucuronide, which may retain partial biological activity. Co-administration with dietary fat or quercetin may modestly inhibit conjugation and enhance free resveratrol absorption.

Preparation & Dosage

No clinically studied dosage ranges are available in the search results. No information on standardized forms, extract potencies, or recommended doses was found. Consult a healthcare provider before starting any new supplement.

Synergy & Pairings

Insufficient research data to recommend synergistic ingredients

Safety & Interactions

Resveratrol is generally considered safe at doses up to 1000 mg per day in short-term studies, with mild gastrointestinal side effects such as nausea and diarrhea reported at higher doses. It inhibits CYP3A4 and CYP2C9 liver enzymes, which can increase plasma levels of drugs including warfarin, statins, and certain calcium channel blockers, raising the risk of adverse effects. Resveratrol has estrogenic activity via binding to estrogen receptors ERα and ERβ, making it potentially contraindicated for individuals with hormone-sensitive conditions such as estrogen receptor-positive breast cancer. Pregnant and breastfeeding women should avoid supplementation due to insufficient safety data.